B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion [Phase 2]
Phase 2 trial evaluating addition of nivolumab to anti-CD-19 CAR-T cells in patients with B cell lymphoma undergoing lymphodepletion.
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART [Phase 2]
Phase 2 trial update evaluating eltrombopag for patients with prolonged bone marrow toxicity after CAR-T therapy.
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating T cells engineered with fully-human anti-CD19 and anti-CD20 CARs for B-cell malignancies and Hodgkin lymphoma; the …
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating allogeneic CD19 CAR-T cells for relapsed/refractory B-cell lymphoma including non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma [Phase 1]
Phase 1 study assessing zanubrutinib in Chinese participants with B-cell lymphoma has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-10-20Clinical Trial Update: CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy [Phase 2]
Phase 2 trial update of CD19-targeting, 3rd generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma [Phase 2]
Phase 2 trial update investigating Orelabrutinib in combination with R2 regimen for relapsed/refractory CD20+ B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating BI-1206 in combination with an anti-CD20 antibody for CD32b-positive B-cell lymphoma or leukemia; study …
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients [Phase 2]
Phase 2 trial evaluating OFATUMUMAB within a reduced intensity conditioning regimen for high-risk B-cell non-Hodgkin lymphoma patients; stud…
-
CLINICAL_TRIALS trial_result · 2021-02-10Clinical Trial Update: Induced-T Cell Like NK Cells for B Cell Malignancies [Phase 1, Phase 2]
A clinical trial update for induced-T cell like NK cells targeting B cell malignancies is underway in Phase 1/Phase 2, with unspecified curr…
-
CLINICAL_TRIALS trial_result · 2021-02-04Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects [Phase 1, Phase 2]
A clinical trial update for a study evaluating BinD19 treatment in relapsed/refractory B-cell ALL and B-cell lymphoma across Phase 1 and Pha…
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Dual Target CAR-T Cells in B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for dual-target CAR-T cells in B-cell lymphoma is ongoing, with the sponsor listed and the status currentl…
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial investigated lenalidomide, ixazomib, and rituximab as front-line therapy for high-risk indolent B-cell lymphoma; the study…
-
CLINICAL_TRIALS trial_result · 2020-11-13Clinical Trial Update: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical study evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory B cell non-Hodgkin lymphoma; status not provided.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study for Patients With Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial update for a study in non-Hodgkin's lymphomas has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of SD-101 with low-dose radiation in untreated low-grade B-cell lymphoma was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA [Phase 3]
Phase 3 trial comparing entecavir and tenofovir regimens in lymphoma patients with active HBV DNA; status not specified.
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma [Phase 1]
Phase 1 trial of anti-CD19 white blood cells in children and young adults with B-cell leukemia or lymphoma completed; results posted in 2020…
-
CLINICAL_TRIALS trial_result · 2020-06-12Clinical Trial Update: Multi-CAR-T Cells Targeting B Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 clinical trial update on multi-CAR-T cells targeting B cell lymphomas; status currently unknown.
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 safety and tolerability study of PCI-32765 in various B-cell malignancies completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]
Phase I/IIA study of CART19 cells in chemotherapy-resistant or refractory CD19+ leukemia and lymphoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas [Phase 1, Phase 2]
A phase 1/2 trial evaluating lenalidomide, methotrexate, cytarabine, and rituximab in relapsed aggressive B-cell lymphomas has been complete…
-
CLINICAL_TRIALS trial_result · 2019-12-23Clinical Trial Update: Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL [Phase 1, Phase 2]
Clinical trial update on CD22 CAR T-cells for B-cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia across Phase 1…
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL [Phase 4]
Phase 4 trial update comparing R2 and combination chemotherapy versus R and combination chemotherapy in newly diagnosed highly aggressive B-…